STOCK TITAN
  1. Home
  2. News
  3. VRTX

Vertex Pharmaceuticals, Inc. - VRTX STOCK NEWS

Welcome to our dedicated news page for Vertex Pharmaceuticals (Ticker: VRTX), a resource for investors and traders seeking the latest updates and insights on Vertex Pharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Vertex Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Vertex Pharmaceuticals's position in the market.

News
VERTEX AND TREEFROG THERAPEUTICS ANNOUNCE LICENSING AGREEMENT AND COLLABORATION TO OPTIMIZE PRODUCTION OF VERTEX'S CELL THERAPIES FOR TYPE 1 DIABETES
Rhea-AI Summary
Vertex Pharmaceuticals and TreeFrog Therapeutics have announced a licensing agreement and collaboration to optimize the production of Vertex's cell therapies for type 1 diabetes. Vertex obtained an exclusive license to TreeFrog's C-StemTM manufacturing technology, and the two companies will work together to scale up the production of fully differentiated, insulin-producing pancreatic islet cells.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
Vertex Announces Advancements of Suzetrigine (VX-548) in Acute and Neuropathic Pain
Rhea-AI Summary
Vertex Pharmaceuticals Incorporated announces significant advancements in its suzetrigine pain program, with FDA granting a rolling NDA submission for moderate-to-severe acute pain and Breakthrough Therapy designation for pain associated with diabetic peripheral neuropathy. Phase 3 program for DPN to start in 2H 2024. Positive Phase 2 results in neuropathic pain. Vertex to continue developing additional pain signal inhibitors for acute and neuropathic pain.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
Vertex Enters Into Agreement to Acquire Alpine Immune Sciences
Rhea-AI Summary
Vertex Pharmaceuticals to Acquire Alpine Immune Sciences for $4.9 Billion: A Strategic Move in Immunotherapy
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
36.9%
Tags
acquisition
News
Vertex Enters Into Agreement to Acquire Alpine Immune Sciences
Rhea-AI Summary
Vertex Pharmaceuticals to Acquire Alpine Immune Sciences for $4.9 Billion in Cash, Focusing on Povetacicept for IgA Nephropathy Treatment
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
36.9%
Tags
acquisition
-
News
Vertex to Announce First Quarter 2024 Financial Results on May 6
Rhea-AI Summary
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will announce its first quarter 2024 financial results on May 6, 2024, after the market closes. A conference call and webcast will follow at 4:30 p.m. ET. Participants can access the call by dialing (833) 630-2124 (U.S.) or +1 (412) 317-0651 (International) and mentioning 'Vertex Pharmaceuticals First Quarter 2024 Earnings Call.' The webcast link will be available on Vertex's website. Registration 15 minutes before the webcast is advised.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.71%
Tags
earnings
-
News
Vertex Advances Inaxaplin (VX-147) into Phase 3 Portion of Adaptive Phase 2/3 Clinical Trial for the Treatment of APOL1-Mediated Kidney Disease
Rhea-AI Summary
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced the advancement of inaxaplin (VX-147) into Phase 3 of the global Phase 2/3 pivotal clinical trial in APOL1-mediated kidney disease. The trial will compare a 45 mg once daily oral dose to placebo, focusing on kidney function and proteinuria. The study has expanded to include adolescents aged 10-17 years. Positive Phase 2a results showed a significant reduction in urine protein to creatinine ratio (UPCR). Inaxaplin aims to address the underlying cause of AMKD, potentially transforming patient care.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.59%
Tags
clinical trial
News
Vertex Announces FDA Clearance of Investigational New Drug Application for VX-407 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Rhea-AI Summary
Vertex Pharmaceuticals announced FDA clearance for VX-407, a first-in-class small molecule corrector targeting ADPKD, a common inherited kidney disease. This marks Vertex's entry into the ADPKD treatment space, addressing the underlying cause of the disease.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.87%
Tags
clinical trial
-
News
Vertex Receives CHMP Positive Opinion for KALYDECO® for the Treatment of Infants With Cystic Fibrosis Ages 1 Month and Older
Rhea-AI Summary
Vertex Pharmaceuticals receives positive opinion for label expansion of KALYDECO® in Europe to treat infants with cystic fibrosis, potentially becoming the first approved medicine for babies as young as 1 month with specific mutations in the CFTR gene.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.78%
Tags
none
-
News
Vertex to Participate in Upcoming Investor Conferences
Rhea-AI Summary
Vertex Pharmaceuticals (VRTX) executives to participate in upcoming investor conferences to discuss company updates and future plans.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.24%
Tags
conferences
News
European Commission Approves First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemcel), for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia
Rhea-AI Summary
Vertex Pharmaceuticals receives conditional marketing authorization for CASGEVY™ in the EU for treating severe sickle cell disease and transfusion-dependent beta thalassemia, potentially benefiting over 8,000 patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.59%
Tags
none
Stock VRTX logo
Vertex Pharmaceuticals, Inc.

Nasdaq:VRTX

VRTX Rankings

#111 Ranked by Market Cap
#1118 Ranked by Stock Gains
N/A Ranked by Dividends

VRTX Stock Data

102.49B
257.56M
0.11%
97.33%
1.54%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Boston

About VRTX

Vertex Pharmaceuticals is an American biopharmaceutical company based in Boston, Massachusetts. It was one of the first biotech firms to use an explicit strategy of rational drug design rather than combinatorial chemistry.